Business Description
Silence Therapeutics PLC
72 Hammersmith Road, London, GBR, W14 8TH
Compare
Compare
Traded in other countries / regions
XRP1.Germany
•
SLN.UK
•
SLNCF.USA
Description
Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid, or siRNA, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical needs. Its income consists of royalty income and revenue from collaboration agreements. Its geographical segments are the United Kingdom, the United States, and Germany.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 658.83 | |||||
| Equity-to-Asset | 0.05 | |||||
| Debt-to-Equity | 0.02 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | -0.96 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -24 | |||||
| 3-Year EPS without NRI Growth Rate | -100 | |||||
| 3-Year Book Growth Rate | -42.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.35 | |||||
| 9-Day RSI | 45.48 | |||||
| 14-Day RSI | 46.32 | |||||
| 6-1 Month Momentum % | -53.41 | |||||
| 12-1 Month Momentum % | -58.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.89 | |||||
| Quick Ratio | 4.89 | |||||
| Cash Ratio | 3.77 | |||||
| Days Sales Outstanding | 27.13 | |||||
| Days Payable | 321.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.1 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 45.35 | |||||
| Operating Margin % | -309.45 | |||||
| Net Margin % | -257.95 | |||||
| ROE % | -294.43 | |||||
| ROA % | -41.09 | |||||
| ROIC % | -227.95 | |||||
| ROC (Joel Greenblatt) % | -2739.99 | |||||
| ROCE % | -58.63 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 31.85 | |||||
| PB Ratio | 121.59 | |||||
| Price-to-Free-Cash-Flow | 137.18 | |||||
| Price-to-Operating-Cash-Flow | 97.27 | |||||
| EV-to-EBIT | -8.82 | |||||
| EV-to-EBITDA | -8.9 | |||||
| EV-to-Forward-EBITDA | -81.94 | |||||
| EV-to-Revenue | 26.95 | |||||
| EV-to-Forward-Revenue | 59.91 | |||||
| EV-to-FCF | 128.26 | |||||
| Earnings Yield (Greenblatt) % | -11.34 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:SLN
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 20.202 | ||
| EPS (TTM) ($) | -1.767 | ||
| Beta | 0 | ||
| Volatility % | 57.93 | ||
| 14-Day RSI | 46.32 | ||
| 14-Day ATR ($) | 1.030554 | ||
| 20-Day SMA ($) | 10.02475 | ||
| 12-1 Month Momentum % | -58.8 | ||
| 52-Week Range ($) | 7.8 - 26.84 | ||
| Shares Outstanding (Mil) | 29.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Silence Therapeutics PLC Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||